Compare Agilent Technologies Inc (A) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Charles Schwab Corporation Common Stock — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Charles Schwab Corporation Common Stock trades at $107.65 (market cap $186.75B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 4.4× Agilent Technologies Inc's market cap, and Charles Schwab Corporation Common Stock pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| A | SCHW | |
|---|---|---|
Market Cap | $42.00B | $186.75B |
Sector | Health | Financials |
52-Week High | $157.20 | $108.02 |
52-Week Low | $110.24 | $85.35 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Charles Schwab (SCHW) trades at $107.60, down 0.06% on the day, near its all-time high of $109.05. The stock shows strong bullish momentum with earnings beats in recent quarters and a consensus analyst price target of $122.33. Revenue grew to $23.92 billion in 2025, with net income margin improving to 38.79%. Technical indicators signal bullish trends, though RSI levels suggest overbought conditions.
Outlook remains positive with robust earnings growth and institutional support, but risks include litigation exposure and competitive pressures. The stock offers upside potential aligned with analyst targets, contingent on sustained operational performance and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
